Cancer drug vorasidenib put to the test: will it clash with common meds?
NCT ID NCT07235748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in 28 healthy adults checks whether the experimental cancer drug vorasidenib changes how the body processes several common medications, including pain relievers, sedatives, and cholesterol drugs. Participants take the other drugs alone and then again with vorasidenib to compare levels in the blood. The goal is to identify potential drug interactions before vorasidenib is used more widely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vorasidenib
- What this could lead to
- If successful, this study will help doctors understand how vorasidenib interacts with other medications, leading to safer dosing guidelines for patients.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. The results may not fully predict effects in people with illness, and drug interactions can still vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Belfast, BT9 6AD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test